Janssen Search
Search results
Healthy Minds & Future Leaders
Janssen’s Healthy Minds Program Awards Future Leaders With Global Mental Health Scholarships Friend, teacher, father, firefighter – serious brain disorders can affect many people we know and love. Millions of people around the world with brain disorders ...
Our Story
We focus our efforts and resources where the need is high, the science is compelling and where we have the greatest opportunity to save and improve lives. Who We Are Who is Janssen? We’re more than 30,000 people working hard to prevent, treat, cure and ...
World Diabetes Day 2016
Janssen Set on Diabetes and Its Life-Threatening Complications Every six seconds someone dies from diabetes. In 2015, diabetes claimed the lives of 5 million people worldwide. As the number of people with diabetes grows, so will this death toll, unless ...
Hematologic Malignancies (Blood Cancers)
Hematologic Malignancies (Blood Cancers) There has been significant progress in the treatment of people diagnosed with blood cancers over the past 50 years. Our leadership has advanced transformative therapies for hematologic malignancies, and we are ...
IDV Newsroom
Welcome to the Janssen Infectious Diseases & Vaccines Virtual Newsroom Janssen’s Commitment to Combating Infectious Diseases A Message from Penny Heaton and James Merson At Janssen, we have a strong legacy of daring to deliver medicines and vaccines ...
Johnson & Johnson pivotal study of seltorexant shows statistically significant and clinically meaningful improvement in depressive symptoms and sleep disturbance outcomes
May 29, 2024 Seltorexant, an investigational first-in-class therapy, met all primary and secondary endpoints in pivotal Phase 3 study in patients with major depressive disorder (MDD) with insomnia symptoms, as presented at ASCP 2024 Approximately 60 ...
Johnson & Johnson Submits Supplemental Biologics License Application and New Drug Application to U.S. FDA Seeking Approval of RYBREVANT® (amivantamab-vmjw) Plus Lazertinib for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
Dec 21, 2023 United States Submissions supported by data from landmark Phase 3 MARIPOSA study, which showed statistically significant and clinically meaningful improvement in progression-free survival in patients with EGFR-mutated advanced NSCLC treated ...
Change Is Coming
Change is Coming. It’s About Time, and We are Ready. Having worked at the Johnson & Johnson Family of Companies for almost 25 years, I've seen first-hand the commitment my company has had to positive change. Because of this, I’m excited to ...
Building a Better Tomorrow for All
Building a Better Tomorrow for All For decades, vaccines have had an unparalleled impact on global public health and remain one of the most effective methods of preventing infectious diseases worldwide. This year, the World Health Organization (WHO) ...
TREMFYA® (guselkumab) Demonstrates Significant and Rapid Scalp Psoriasis Clearance in People of Color in New Large Phase 3b Study
Jan 22, 2024 United States Data illustrates rapid and significant clearance in moderate to severe scalp psoriasis and significant improvement in scalp itch, as well as patient-reported health-related quality of life outcomes, including post-inflammatory ...